CD38 and Miyoshi myopathy: To date, MM remains incurable despite the greatly improved clinical perspective due to novel immunomodulatory agents like lenalidomide and pomalidomide and highly promising antibodies like daratumumab (anti-CD38) and elotuzumab (anti-CS-1/SLAMF7).